Global Chronic Pancreatitis CP Trends 2025, Forecast To 2034
26 Mar, 2025
What Is The Current and Historic Market Size Analysis Of The Chronic Pancreatitis CP Market?
The chronic pancreatitis cp market has seen considerable growth due to a variety of factors.
• Over the preceding years, the market size for chronic pancreatitis (CP) has seen robust expansion. The market size is projected to rise from $4.91 billion in 2024 to $5.25 billion in 2025, showcasing a compound annual growth rate (CAGR) of 6.7%.
The historical growth phase is associated with an increased trend in alcohol consumption, surge in incidents of smoking, genetic factors, and familial background. Other contributing factors include heightened awareness regarding pancreatic diseases, a rise in the number of diabetes cases connected to pancreatitis, augmented healthcare expenditure, along with better access to healthcare services.
What Is The Forecast For The Chronic Pancreatitis CP Market?
The chronic pancreatitis cp market is expected to maintain its strong growth trajectory in upcoming years.
• The market for chronic pancreatitis (CP) is anticipated to witness robust growth in the coming years, with its market size projected to reach $6.72 billion in 2029, growing at a compound annual growth rate (CAGR) of 6.4%.
This growth during the forecast period could be a result of factors such as the increasing elderly population, heightened demand for enzyme replacement therapies, rising emphasis on early diagnosis, the expansion of healthcare systems in emerging markets, the emergence of innovative pain therapies, and an increase in scientific and clinical trials regarding pancreatitis treatment. The upcoming trends during this forecast period include the application of artificial intelligence in diagnostic imaging, the adoption of minimally invasive surgical procedures, the use of wearable devices for consistent health monitoring, the implementation of next-generation sequencing for genetic testing, the inclusion of machine learning in disease progression tracking, and the creation of advanced diagnostic instruments.
What Are The Leading Drivers Of Growth In The Chronic Pancreatitis CP Market?
The anticipated expansion of the chronic pancreatitis market is intrinsically linked to the rise in alcohol consumption. When people drink beverages containing ethanol, whether for enjoyment, social reasons, or as part of their culture, it can lead to health hazards or dependency if taken in excess. The surge in alcohol intake is influenced by greater social acceptance, urbanization, lifestyle changes, and stress management habits, particularly in the younger generation. Inflammation and damage to the pancreatic cells, resulting from alcohol consumption, cause chronic pancreatitis. This leads to fibrosis, ductal blockages, and long-term dysfunction due to harmful metabolic by-products. For example, a report published by Kirin Holdings Company Limited, a Japanese beer and beverage company, in December 2023 showed that global beer consumption in 2022 increased by around 5.4 million kiloliters (equivalent to nearly 8.5 billion 633ml bottles) from 2021's figures, totalling to roughly 192.1 million kiloliters. This 2.9% growth was primarily due to COVID-19 related restrictions being eased, with the total consumption reaching around 303.5 billion 633ml bottles. Thus, the upswing in alcohol consumption is fuelling the expansion of the chronic pancreatitis market.
How Is The Global Chronic Pancreatitis CP Market Divided Into Key Segments?
The chronic pancreatitis (CP) market covered in this report is segmented –
1) By Treatment: Analgesic, Artificial Digestive Enzyme, Protein Supplements, Steroids, Antibiotics, Other Treatments
2) By Diagnosis: Computed Tomography (CT) Scan, Magnetic Resonance Cholangiopancreatography, Ultrasound Sonography, Other Diagnosis
3) By Route Of Administration: Oral, Parenteral
4) By End User: Hospitals, Homecare, Other End Users
Subsegments:
1) By Analgesic: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Opioids
2) By Artificial Digestive Enzyme: Pancrelipase, Pancreatin
3) By Protein Supplements: Branched-Chain Amino Acids (BCAA), Whey Protein
4) By Steroids: Prednisone, Dexamethasone
5) By Antibiotics: Ciprofloxacin, Metronidazole
6) By Other Treatments: Endoscopic Treatment, Surgery
What Trends Are Reshaping The Future Of The Chronic Pancreatitis CP Market?
Key players in the chronic pancreatitis market are concentrating on the creation of technological advances such as enzyme replacement therapy to deal with the exocrine pancreatic insufficiency (EPI) linked to chronic pancreatitis. This therapy involves patients with low pancreatic function consuming oral pancreatic enzymes to assist digestion. For instance, First Wave BioPharma Inc, an American clinical-stage biopharmaceutical firm, unveiled the results of the Phase 2 SPAN clinical trial in July 2023. This trial examined an improved enteric microgranule delivery formulation of adrulipase used to treat EPI in patients who have cystic fibrosis (CF) and chronic pancreatitis. Adrulipase, a lipase enzyme that originates from the Yarrowia lipolytica yeast, is given as an oral, non-systemic biologic capsule. It is specially designed to dismantle fat molecules in the digestive tract of EPI patients which can then be absorbed as nutrients.
Who Are the Key Players In The Chronic Pancreatitis CP Market?
Major companies operating in the chronic pancreatitis (CP) market are:
• Pfizer
• Johnson & Johnson
• Merck & Co Inc
• AbbVie Inc
• Sanofi
• Bristol-Myers Squibb
• Abbott Laboratories
• Novartis AG
• GlaxoSmithKline plc
• Baxter
• CSL Behring
• Octapharma AG
• Dr. Reddy's Laboratories
• Nestle Health Science
• Cerata Pharmaceuticals
• Unichem Laboratories Ltd
• LGM Pharma
• Aptalis Pharmaceutical Technologies
• Digestive Care Inc
• Akron Biotech
What Are The Regional Insights Into The Chronic Pancreatitis CP Market?
North America was the largest region in the chronic pancreatitis (CP) market in 2024. The regions covered in the chronic pancreatitis (cp) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.